Faraday Pharmaceuticals Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 27

Employees

  • Latest Deal Type
  • Debt

  • Latest Deal Amount
  • $1.65M

  • Investors
  • 7

Faraday Pharmaceuticals General Information

Description

Developer of novel therapeutics designed to offer elemental reducing agents. The company's therapeutics are focused on the ability of specific reduced forms of elements to improve outcomes for patients, enabling medical practitioners to treat ischemia-reperfusion injury and other critical care illnesses in a simplified manner.

Contact Information

Formerly Known As
Scion Pharmaceuticals
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1616 Eastlake Avenue East
  • Suite 560
  • Seattle, WA 98102
  • United States
+1 (206)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Vertical(s)
Corporate Office
  • 1616 Eastlake Avenue East
  • Suite 560
  • Seattle, WA 98102
  • United States
+1 (206)

Faraday Pharmaceuticals Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Faraday Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Debt - General 01-Jan-2024 $1.65M Completed Clinical Trials - Phase 3
4. Debt - General 01-Jan-2023 Completed Clinical Trials - Phase 3
3. Later Stage VC (Series C) 07-Nov-2022 Completed Clinical Trials - Phase 3
2. Early Stage VC (Series B) 12-Sep-2019 $30.1M $62.7M Completed Clinical Trials - Phase 3
1. Early Stage VC (Series A) 21-Feb-2017 $32.6M $32.6M Completed Startup
To view Faraday Pharmaceuticals’s complete valuation and funding history, request access »

Faraday Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C-1
Series C
Series B 21,872,076 $0.000100 8% $1.31 $1.31 1x $1.31 12.3%
Series A 32,775,844 $0.000100 8% $1 $1 1x $1 18.43%
To view Faraday Pharmaceuticals’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Faraday Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of novel therapeutics designed to offer elemental reducing agents. The company's therapeutics are focused on t
Drug Discovery
Seattle, WA
27 As of 2025

Carlsbad, CA

Watertown, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Faraday Pharmaceuticals Competitors (75)

One of Faraday Pharmaceuticals’s 75 competitors is Renova Therapeutics, a Venture Capital-Backed company based in Carlsbad, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Renova Therapeutics Venture Capital-Backed Carlsbad, CA
EyePoint Corporation Watertown, MA
Ardelyx Formerly VC-backed Waltham, MA
Pacira BioSciences Formerly VC-backed Tampa, FL
Amryt Pharma Corporate Backed or Acquired London, United Kingdom
You’re viewing 5 of 75 competitors. Get the full list »

Faraday Pharmaceuticals Patents

Faraday Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025222169-A1 S-oxprenolol for preserving muscle mass, bone density, and cardiac function in weight loss treatments Pending 19-Apr-2024
WO-2025222169-A9 S-oxprenolol for preserving muscle mass, bone density, and cardiac function in weight loss treatments Pending 19-Apr-2024
GB-202301180-D0 Salt of a pharmaceutical compound Inactive 27-Jan-2023
AU-2024212388-A1 Salt of s-oxprenolol Pending 27-Jan-2023
EP-4441028-A1 Salt of s-oxprenolol Active 27-Jan-2023 A61K31/138
To view Faraday Pharmaceuticals’s complete patent history, request access »

Faraday Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Faraday Pharmaceuticals Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
The University of Tokyo Edge Capital Venture Capital Minority
5AM Ventures Venture Capital Minority
Alexandria Real Estate Equities Real Estate Minority
ARCH Venture Partners Venture Capital Minority
Osage University Partners Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

Faraday Pharmaceuticals FAQs

  • When was Faraday Pharmaceuticals founded?

    Faraday Pharmaceuticals was founded in 2014.

  • Where is Faraday Pharmaceuticals headquartered?

    Faraday Pharmaceuticals is headquartered in Seattle, WA.

  • What is the size of Faraday Pharmaceuticals?

    Faraday Pharmaceuticals has 27 total employees.

  • What industry is Faraday Pharmaceuticals in?

    Faraday Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Faraday Pharmaceuticals a private or public company?

    Faraday Pharmaceuticals is a Private company.

  • What is Faraday Pharmaceuticals’s current revenue?

    The current revenue for Faraday Pharmaceuticals is .

  • How much funding has Faraday Pharmaceuticals raised over time?

    Faraday Pharmaceuticals has raised $120M.

  • Who are Faraday Pharmaceuticals’s investors?

    The University of Tokyo Edge Capital, 5AM Ventures, Alexandria Real Estate Equities, ARCH Venture Partners, and Osage University Partners are 5 of 7 investors who have invested in Faraday Pharmaceuticals.

  • Who are Faraday Pharmaceuticals’s competitors?

    Renova Therapeutics, EyePoint, Ardelyx, Pacira BioSciences, and Amryt Pharma are some of the 75 competitors of Faraday Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process